Characterization of currently marketed heparin products: Key tests for quality assurance

Analytical and Bioanalytical Chemistry

Volumn 399, Issue 2, 2011, Pages 581-591

  Keire, David A ^a   Ye, Hongping ^a   Trehy, Michael L ^a   Ye, Wei ^a   Kolinski, Richard E ^a   Westenberger, Benjamin J ^a   Buhse, Lucinda F ^a   Nasr, Moheb ^a   Al Hakim, Ali ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

CE; Factor IIa Xa; Heparin; NMR; OSCS; SAX HPLC

Indexed keywords

CE; FACTOR IIA/XA; HEPARIN; NMR; OSCS; SAX-HPLC;

DRUG PRODUCTS; IMPURITIES; QUALITY ASSURANCE; SODIUM; SODIUM SULFATE; SUPPLY CHAINS;

POLYSACCHARIDES;

ANTICOAGULANT AGENT; CHONDROITIN SULFATE; HEPARIN;

ARTICLE; CAPILLARY ELECTROPHORESIS; CHEMISTRY; COMPARATIVE STUDY; DRUG CONTAMINATION; FOOD AND DRUG ADMINISTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; QUALITY CONTROL; UNITED STATES;

ANTICOAGULANTS; CHONDROITIN SULFATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; ELECTROPHORESIS, CAPILLARY; HEPARIN; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; QUALITY CONTROL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79251634435     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-010-4023-y     Document Type: Article

References (34)

1. H Liu Z Zhang RJ Linhardt 2009 Lessons learned from the contamination of heparin Nat Prod Rep 26 313 321 1:CAS:528:DC%2BD1MXisVGjsL8%3D 10.1039/b819896a
2. DL Rabenstein 2002 Heparin and heparan sulfate: structure and function Nat Prod Rep 19 312 331 1:CAS:528:DC%2BD38XlsFSnsbY%3D 10.1039/b100916h
3. KG Fischer 2007 Essentials of anticoagulation in hemodialysis Hemodial Int 11 178 189 10.1111/j.1542-4758.2007.00166.x
4. NE Lepor 2007 Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors Rev Cardiovasc Med 8 Suppl 3 S9 S17
5. DA Keire DJ Mans H Ye RE Kolinski LF Buhse 2010 Assay of possible economically motivated additives or native impurities levels in heparin by 1H NMR, SAX-HPLC, and anticoagulation time approaches J Pharm Biomed Anal 52 656 664 1:CAS:528:DC%2BC3cXksVamsrs%3D 10.1016/j.jpba.2010.02.019
6. USP (2008) In: Heparin Sodium. (Ed.)^(Eds.), United States Pharmacopeia National Formulary 31 NF 26, Rand McNally, Rockville, MD, pp. 2321-2322 (May 1)
7. WHO 2008 Acute allergic-type reactions among patients undergoing hemodialysis-multiple states MMWR Morb Mortal Wkly Rep 57 124 125
8. CT Laurencin L Nair 2008 The FDA and safety-beyond the heparin crisis Nat Biotechnol 26 621 623 1:CAS:528:DC%2BD1cXmvVCjtrg%3D 10.1038/nbt0608-621
9. U.S. Department of Health and Human Services USFDA (November 2009) Information on adverse event reports and heparin. http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPateintsandProviders/UCM112669
10. M Guerrini D Beccati Z Shriver A Naggi K Viswanathan A Bisio I Capila JC Lansing S Guglieri B Fraser A Al-Hakim NS Gunay Z Zhang L Robinson L Buhse M Nasr J Woodcock R Langer G Venkataraman RJ Linhardt B Casu G Torri R Sasisekharan 2008 Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events Nat Biotechnol 26 669 675 1:CAS:528:DC%2BD1cXmvVCisrY%3D 10.1038/nbt1407
11. TK Kishimoto K Viswanathan T Ganguly S Elankumaran S Smith K Pelzer JC Lansing N Sriranganathan G Zhao Z Galcheva-Gargova A Al-Hakim GS Bailey B Fraser S Roy T Rogers-Cotrone L Buhse M Whary J Fox M Nasr GJ Dal Pan Z Shriver RS Langer G Venkataraman KF Austen J Woodcock R Sasisekharan 2008 Contaminated heparin associated with adverse clinical events and activation of the contact system N Engl J Med 358 2457 2467 1:CAS:528:DC%2BD1cXmvFKmtb4%3D 10.1056/NEJMoa0803200
12. A Adam N Montpas D Keire A Desormeaux NJ Brown F Marceau B Westenberger 2010 Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro Biomaterials 31 5741 5748 1:CAS:528: DC%2BC3cXmtlKitrc%3D 10.1016/j.biomaterials.2010.03.074
13. TE Warkentin A Greinacher 2009 Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes Expert Opin Drug Saf 8 129 144 1:CAS:528:DC%2BD1MXjsVOhsrs%3D 10.1517/14740330902778180
14. 1H-nuclear magnetic resonance spectroscopy J Pharm Sci 78 101 104 1:CAS:528:DyaL1MXht1WmsLs%3D 10.1002/jps.2600780205
15. RJ Linhardt KG Rice YS Kim DL Lohse HM Wang D Loganathan 1988 Mapping and quantification of the major oligosaccharide components of heparin Biochem J 254 781 787 1:CAS:528:DyaL1cXlvVKktLY%3D
16. 1H nuclear magnetic resonance spectroscopy J Pharm Biomed Anal 48 13 19 1:CAS:528:DC%2BD1cXhtVartrfK 10.1016/j.jpba.2008.06.014
17. DA Keire ML Trehy JC Reepmeyer RE Kolinski W Ye J Dunn BJ Westenberger LF Buhse 2010 Analysis of crude heparin by (1)H NMR, capillary electrophoresis, and strong-anion-exchange-HPLC for contamination by over sulfated chondroitin sulfate J Pharm Biomed Anal 51 921 926 1:CAS:528:DC%2BD1MXhs1WgsbfF 10.1016/j.jpba.2009.10.017
18. J Chen FY Avci EM Munoz LM McDowell M Chen LC Pedersen L Zhang RJ Linhardt J Liu 2005 Enzymatic redesigning of biologically active heparan sulfate J Biol Chem 280 42817 42825 1:CAS:528:DC%2BD2MXhtlCmsLfM 10.1074/jbc.M504338200
19. USP (2009) Heparin Sodium. United States Pharmacopeial Forum 35(2) (March-April)
20. B Mulloy MJ Forster 2000 Conformation and dynamics of heparin and heparan sulfate Glycobiology 10 1147 1156 1:CAS:528:DC%2BD3cXosVOjtb0%3D 10.1093/glycob/10.11.1147
21. B Mulloy MJ Forster C Jones DB Davies 1993 NMR and molecular-modeling studies of the solution conformation of heparin Biochem J 293 Pt 3 849 858 1:CAS:528:DyaK3sXltlWhtL4%3D
22. Dionex (2009) Determination of galactosamine containing organic impurities in heparin by HPAE-PAD using the CarboPac PA20 column. Application Note 233
23. T Maruyama T Toida T Imanari G Yu RJ Linhardt 1998 Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation Carbohydr Res 306 35 43 1:CAS:528:DyaK1cXksFCit78%3D 10.1016/S0008-6215(97) 10060-X
24. T Toida T Maruyama Y Ogita A Suzuki H Toyoda T Imanari RJ Linhardt 1999 Preparation and anticoagulant activity of fully O-sulphonated glycosaminoglycans Int J Biol Macromol 26 233 241 1:CAS:528:DyaK1MXmvVyhurw%3D 10.1016/S0141-8130(99)00088-4
25. ML Trehy JC Reepmeyer RE Kolinski BJ Westenberger LF Buhse 2009 Analysis of heparin sodium by SAX/HPLC for contaminants and impurities J Pharm Biomed Anal 49 670 673 1:CAS:528:DC%2BD1MXivVGjtr8%3D 10.1016/j.jpba.2008.12.013
26. I McEwen B Mulloy E Hellwig L Kozerski T Beyer U Holzgrabe R Wanko JM Spieser A Rodomonte 2008 Determination of oversulphated chondroitin sulphate and dermatan sulphate in unfractionated heparin by (1)H-NMR-collaborative study for quantification and analytical determination of LoD Pharmeur Bio 2008 31 39 1:STN:280:DC%2BD1M7lt1Cgsg%3D%3D
27. J Pan Y Qian X Zhou A Pazandak SB Frazier P Weiser H Lu L Zhang 2010 Oversulfated chondroitin sulfate is not the sole contaminant in heparin Nat Biotechnol 28 203 207 1:CAS:528:DC%2BC3cXivV2rsbc%3D 10.1038/nbt0310-203 author reply 207-211
28. M Guerrini Z Zhang Z Shriver A Naggi S Masuko R Langer B Casu RJ Linhardt G Torri R Sasisekharan 2009 Orthogonal analytical approaches to detect potential contaminants in heparin Proc Natl Acad Sci USA 106 16956 16961 1:CAS:528:DC%2BD1MXhtlaks7fI 10.1073/pnas.0906861106
29. F Fernandez J Van Ryn FA Ofosu J Hirsh MR Buchanan 1986 The haemorrhagic and antithrombotic effects of dermatan sulphate Br J Haematol 64 309 317 1:CAS:528:DyaL2sXktFw%3D 10.1111/j.1365-2141.1986.tb04124.x
30. J Folkman R Langer RJ Linhardt C Haudenschild S Taylor 1983 Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone Science 221 719 725 1:CAS:528:DyaL3sXltFGlu70%3D 10.1126/science.6192498
31. RE Merton DP Thomas 1987 Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents Thromb Haemost 58 839 842 1:CAS:528:DyaL1cXkvFSguw%3D%3D
32. M Guerrini A Naggi S Guglieri R Santarsiero G Torri 2005 Complex glycosaminoglycans: profiling substitution patterns by two-dimensional nuclear magnetic resonance spectroscopy Anal Biochem 337 35 47 1:CAS:528: DC%2BD2MXksVCgtg%3D%3D 10.1016/j.ab.2004.10.012
33. JE Camara MB Satterfield BC Nelson 2007 Quantitative determination of disaccharide content in digested unfragmented heparin and low molecular weight heparin by direct-infusion electrospray mass spectrometry J Pharm Biomed Anal 43 1706 1714 1:CAS:528:DC%2BD2sXjsVGgt7k%3D 10.1016/j.jpba.2007.01.006
34. TR Rudd MA Skidmore SE Guimond C Cosentino G Torri DG Fernig RM Lauder M Guerrini EA Yates 2009 Glycosaminoglycan origin and structure revealed by multivariate analysis of NMR and CD spectra Glycobiology 19 52 67 1:CAS:528:DC%2BD1cXhsV2rs77F 10.1093/glycob/cwn103